SUMMARY At least 8% of the human genome was formed by integration of retroviral DNA sequences. These sequences are remnants of ancient infections that have accumulated mutations over millions of years.
UJEMI-PEARLS
Human Endogenous Retroviruses as Contributors of Exosomemediated Autoimmunity in Systemic Lupus Erythematosus
Wednesday, September 5, 2018
Volume 3
Fall 2017 / Winter 2018
Targeting the Gut Microbiome in HIV/AIDS: New Therapeutic Opportunities
Wednesday, September 5, 2018
Volume 3
Fall 2017 / Winter 2018
SUMMARY Despite major advances in HIV antiretroviral therapy (ART), complete elimination of the disease has not been achieved. Recently, the importance of the gutassociated lymphoid tissues (GALT) and the resident microbiota in HIV pathogenesis has been highlighted.
Multiple Sclerosis Associated Retrovirus as a Prognostic Biomarker for Prescribing Disease Modifying Therapies in Multiple Sclerosis
Sunday, August 27, 2017
Volume 2
Fall 2017 / Winter 2018
Multiple Sclerosis (MS) is a disease of the central nervous system with unknown etiology.
Biological Individuality: The Microbiome as a Dynamic in HCV Liver Disease Progression
Friday, July 14, 2017
Volume 2
Fall 2016 / Winter 2017
The precision medicine initiative was established to optimize patient outcomes through studying variations between individuals as a “one-size-fits-all” approach is seldom useful in disease treatment.
Written in Blood: Liquid Biopsies for Cervical Cancer Screening
Friday, July 14, 2017
Volume 2
Fall 2016 / Winter 2017
Cervical cancer (CC) is one of the most common malignancies affecting women across the world. The major cause of CC is human papillomavirus (HPV) infection. Studies have shown that HPV infection is highly correlated (>99%) with the occurrence of CC.
Long Non-coding RNAs As Novel Therapeutic Agents and Biomarkers for Treating Epstein-Barr Virus Associated Diffuse Large B-cell Lymphoma
Friday, July 14, 2017
Volume 2
Fall 2016 / Winter 2017
Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin’s lymphoma. It is clinically heterogeneous and highly aggressive, and may develop resistance upon relapse. Current treatments, although effective, are hampered by the robust nature of the cancer.
Leveraging Cloud Computing for Genome Analysis to Provide Patient-Specific HIV Treatments and Insight Into HIV Susceptibility Patterns
Friday, July 14, 2017
Volume 2
Fall 2016 / Winter 2017
Due to its high mutation rate, HIV-1 currently stands as one of the most difficult viruses for treating and vaccinating. Resistance to the limited repertoire of treatments is also well documented.
Disease Management for Adenovirus 36-Induced Obesity
Friday, July 14, 2017
Volume 2
Fall 2016 / Winter 2017
Global obesity rates continue to increase exponentially with no effective, cause-specific treatment or prevention strategies currently available. The recent trends in obesity prevalence suggest that obesity may have an infectious origin, termed infectobesity.
Novel Omics Strategies To Combat Dengue Infection and Disease Progression
Thursday, July 13, 2017
Volume 2
Fall 2016 / Winter 2017
The dengue virus (DENV) is a continuing global health threat rapidly spreading from its origins in tropical and subtropical regions. The virus is capable of causing severe and life-threatening diseases including dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS).
Novel Genomics Strategies for Clinical Prognosis in Early- Stages of ZIKV Infections: The Search for New ZIKVAssociated Disease Biomarkers
Thursday, July 13, 2017
Volume 2
Fall 2016 / Winter 2017
Zika virus (ZIKV) is an arthropod-borne virus (arbovirus) belonging to the Flavivirus genus that has quickly become one of the most prominent viral health concerns in recent history.